Fort Lauderdale, Florida–(Newsfile Corp. – August 17, 2023) – Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution, has entered a partnership with TruHC Pharma GmbH (“TruHC”), a medical cannabis expert based in Hamburg, Germany. TruHC holds an EU-GDP certification as an importer, distributor and manufacturer of medical cannabis, and operates a production facility with a cutting-edge cannabis laboratory for which an EU-GMP license is expected by the end of September.

Mr. Hendrik Knopp, a respected lawyer and accomplished entrepreneur, along with the TruHC team, joins the Flora family. Mr. Knopp’s leadership has been pivotal in establishing Germany’s medical cannabis landscape, including securing one of the first cultivation licenses in the country.

“I am delighted to welcome Hendrik Knopp and the TruHC team to the Flora group. Their expertise and achievements within the industry, particularly in pioneering medical cannabis in Germany, make them invaluable partners,” stated Clifford Starke, Chief Executive Officer of Flora.

As Germany and the European Union move towards the de-scheduling of narcotics, facilitating improved patient access, Mr. Knopp, Chief Executive Officer of TruHC, expressed his anticipation: “I am excited to collaborate with Flora as we navigate the evolving landscape of medical cannabis. The potential for easier patient access presents a compelling opportunity to contribute to the remarkable growth of this industry.”

“We are poised to execute our strategic business plan and capture a meaningful market share in Germany,” affirmed Clifford Starke.

About Flora Growth Corp.

Flora Growth Corp. is a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution. For more information on Flora, visit www.floragrowth.com.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9845/177618_image1_550.jpg

https://justcbdstore.com/

https://www.vesselbrand.com/

https://justcbdstore.uk/

https://www.phatebo.de/home-en

Investor Relations:

Investor Relations ir@floragrowth.com

Clifford Starke Clifford.Starke@floragrowth.com

Media:

media@floragrowth.com

Cautionary Statement Concerning Forward-Looking Statements

This press release contains “forward looking statements,” as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward looking statements are subject to various and risks and uncertainties, including those described under section entitled “Risk Factors” in Flora’s Annual Report on Form 10K filed with the SEC on March 31, 2023, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. While forward looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based on information currently available to Flora (or to third parties making the forward-looking statements).

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

On the heels of Lift Toronto 2023, which took place June 1-3, gathering a robust audience from across the cannabis industry and community for education, exhibits and top-tier networking, Lift Events & Experiences announces a game-changing new partnership and key enhancements to its upcoming U.S. debut.

Continuing its mission to “lift the cannabis industry across North America,” Lift will soon make its way to a key location in the stateside legalization movement. The team behind the events recognizes a great responsibility to both new and returning audiences, as well as to California’s deep-rooted cannabis legacy.

Lift San Francisco will include the Lift Expo, scheduled for Thursday, August 3 and Friday, August 4, 2023. The Lift Cannabis Business Conference (previously scheduled during a pre-show period prior to the expo) will take place Thursday, August 3, as a combined event with a new Investment Summit presented in partnership with The Arcview Group.

Recognized as a pioneer in cannabis and hemp industry investment content, The Arcview Group has been a trusted global leader for over ten years and a nexus for investors, companies, entrepreneurs and community. Together, the new partners prioritize social justice and responsibility, with The Arcview Group providing a broad spectrum of programs and services across a vertically integrated organization. The Arcview Investment Summit will take place alongside the Lift Cannabis Business Conference, combining two synergistic education opportunities, including enhanced investment-centered content for audiences across the cannabis and hemp industries.

“Lift is honored to welcome our new partners, The Arcview Group,” says Lift Events & Experiences Portfolio Lead, Lindsay Roberts. “Through extensive research and the expert counsel of our North American Advisory Board, we know that investment content is a ‘must’ for serving Lift’s California and U.S.-wide audience. There is no better source for this crucial, timely information than The Arcview Group.”

“We are excited to work with Lift. Having produced 50 investor conferences over the last 13 years, it’s important that investors, entrepreneurs, and operators can experience our unique content at major industry events,” says The Arcview Group CEO Jeffrey Finkle. “Partnering with Lift on a combined conference in San Francisco will help us realize that goal.”.

The combined Lift Cannabis Business Conference and Arcview Investment Summit will be followed by the buzzworthy new Taste at Lift: Cannabis Food & Beverage Experience on Friday, August 4. All Lift San Francisco educational and expo activities will take place at San Francisco’s Moscone Convention Center and will be complemented by Lift’s famously irresistible atmosphere and best-in-class networking opportunities.

Thursday, August 3, 2023 | Lift Cannabis Business Conference and Arcview Investment Summit

Lift’s strategy-focused, advocacy-oriented business and community leadership conference and The Arcview Group’s leading-edge cannabis industry investment program combine into one high-impact day of essential education. Attendees will gain the information needed to navigate today’s cannabis market and investment climate in California and beyond.

Friday, August 4, 2023 | Taste at Lift: Cannabis Food & Beverage Experience

Premiering at Lift San Francisco 2023, this first-of-its-kind event offers an unparalleled experience including tastings, presentations and expert panels featuring the world’s leaders in cannabis food, beverage and hospitality. Guests are invited to learn and engage at the forefront of this emerging sector through first-hand lessons learned, expected obstacles and success stories.

Thursday, August 3 & Friday, August 4 | Lift Expo Days

Exhibitors at the Lift San Francisco cannabis tradeshow will span the full cannabis ecosystem, offering the latest products, services and innovations. Brands, growers and producers will showcase live flower on the expo floor to see, touch and smell; speakers and panels will be featured each day; plus, attendees can expect the unexpected with Lift’s famous atmosphere and ah-ha! moments.

Thursday, August 3 & Friday, August 4 | Receptions & Official After Party

Receptions each day will create ideal opportunities for industry members and attendees to continue conversations and make meaningful, business-building connections. At the close of Lift San Francisco, the Lift Official After Party will serve up food, drink and music to end the event on a high note.

Lift San Francisco Tickets are available now and Exhibits and Partnerships are available. Click here for additional details.

Lift Events by the Numbers

3K+ Attendees*

2 Days of Exclusive Cannabis Industry Education

2 Days of Exhibits, Attractions and Activations

100+ Speakers*

100+ Exhibiting Companies*

2 Industry Networking Receptions and 1 Amazing After Party

Lift Industry Attendees Snapshot**

27% Own or Represent Producers

48% C-Suite, Owner or Founder

54% Purchasing Decision-Makers

80% Plan to Follow Up with Exhibitors After the Show

Lift Events & Experiences 2023 North American Advisory Board

Deepak Anand, Head of International Consulting, Gateway Proven Strategies

David Brown, Cannabis Policy Analyst & Founder, StratCann

Adelia Carrillo, Founder, EventHi

Chris Day, CEO, Gateway Proven Strategies

Christine De La Rosa, CEO, The People’s Ecosystem

Jill Ellsworth, CEO, Willow Industries

Jillian Reddish, Co-Founder, Global Cannabis Network Collective

Jesce Horton, CEO, Lowd

Mariana Larrea, Attorney; Founder, AMENIC

Nathan Mison, CEO, Diplomat Consulting

Gia Morón, CEO, Women Grow

Jamie Pearson, CEO, New Holland Group

Shanita Penny, Founder/Principal, Budding Solutions

Amna Shamim, Chief Growth Officer, Parsl

Dana Shoched, President & CEO, O2VAPE

David Tran, Founder, Farechild

*Based on most recent event data.  **Based on most recent post-show poll data.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Launches Turn-Key Contract Development and Manufacturing Plus Distribution (CDMO+D) Solution for Industry Leading Hemp/Cannabis Brands

Highly Accretive Transformative Deal Utilizes Entire 22nd Century Value Chain, from Receptor Science to Category Management in Retail Distribution with Most Recognized Cannabis Brand in the World

BUFFALO, N.Y., April 05, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced a new three-year exclusive license and distribution agreement (the “Agreement”) with Cookies, the most globally recognized hemp/cannabis company in the world. The brand was founded in 2010 by chief executive officer, rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai.

“This transformational strategic license, manufacturing and distribution agreement with Cookies establishes the foundation of an innovative new CDMO plus distribution business model for 22nd Century at a time when mass market channels urgently need to find new, high-margin, high-velocity products to meet the rapidly growing consumer demand for CBD products,” said James A. Mish, Chief Executive Officer of 22nd Century. “Our complete, vertically integrated capabilities represent the first and only industry option providing Cookies’ category leading, CBD brand with a single-source, national solution across its entire family of products.”

“We are incredibly excited to expand our partnership beyond GVB with the 22nd Century Group. They have undoubtedly put together one of the most impressive teams in the space, and we look forward to expanding the national distribution of Cookies non-THC products together,” said Parker Berling, President of Cookies.

The exclusive license with 22nd Century covers all Cookies branded non-Delta-9 THC, hemp derived cannabinoid consumer packaged goods, including sourcing of all ingredients and APIs; white-label manufacturing of vapes and other CBD products; and category management through retail distribution.

GVB Biopharma, a 22nd Century company, has manufactured various Cookies products for the past three years, and under this new Agreement, will manufacture Cookies’ market-leading products, expected to account for more than half of Cookies’ non-Delta-9 cannabinoid sales.

The integrated go-to-market sales and distribution components of the agreement will leverage 22nd Century’s veteran consumer packaged goods (“CPG”) sales team, which plans to distribute Cookies products in up to 18 markets targeted for the rollout of the Company’s innovative VLN^® products, during 2023. This combination will allow Cookies to leverage 22nd Century’s purpose built, turn-key sales and distribution platform for alternative consumer products.

Cookies will continue to leverage its robust brand building, marketing and advertising apparatus to support sales of its products, including, but not limited to, direct advertising of their products by Berner across social media, earned media and in-person events. The partnership will also leverage Cookies’ industry leading creative development studios across a number of different placements and categories to promote product launches in key markets.

The CPG sales team will target a market of approximately 60,000 retail stores consisting of independent retail, discount tobacco outlets and vape shops in non-recreational states serviced by its network of top regional distributors and chain discount tobacco outlets. Products will also be available on the Cookies e-commerce website: https://shop.cookies.co/.

“Cookies products are a natural fit to the same points of sale as our FDA MRTP authorized VLN^® products. The combination of these two offerings will enhance our sales team’s product portfolio with a larger suite of small-footprint, high-velocity, high-margin CBD products, with Cookies’ internationally recognized products serving as a cornerstone brand as we build out this innovative hemp/cannabis CDMO+D platform,” said John Miller, President of Tobacco Products of 22nd Century.

About Cookies
Cookies, founded in 2010 by Billboard-charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai, is the most globally recognized cannabis company in the world. Cookies values the power of the plant and focuses on creating game-changing genetics. The company offers a collection of over 70 proprietary cannabis cultivars and more than 2,000 products. Cookies also actively works to enrich communities disproportionately impacted by the War on Drugs through advocacy and social equity initiatives. Headquartered in San Francisco, the company opened its first retail store in 2018 in Los Angeles, and has since expanded to 58 retail locations in 18 markets across 6 countries. Cookies was named one of America’s Hottest Brands of 2021 by AdAge; the first cannabis brand to ever receive this accolade. To learn more about Cookies, visit cookies.co, and to learn more about Cookies CBD, visit shop.cookies.co.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading biotechnology company focused on utilizing advanced alkaloid plant technologies to improve health and wellness through tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and hops. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 9, 2023. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
22nd Century Group, Inc.
Investor Relations
mkreps@xxiicentury.com
214-597-8200

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Partnership with Atlas to focus on U.S. market with immediate sales and marketing of U.S. Government approved products and laboratory collaboration to secure further FDA approvals

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory – today announced that it signed a partnership agreement with Alp Medtech AG (“ALP’) – the authorized representative of Atlas Medical Gmbh (“Atlas”), a European medical device company specializing in the distribution and manufacturing of invitro diagnostic tests and medical devices.

Atlas was founded in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and kits. Their products are sold in more than 80 countries worldwide. Their product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. Atlas has leading experience in technologies used in manufacturing diagnostic products such as clinical chemistry, nano-beads serology, immunoassays including ELISA and lateral flow rapid tests. Atlas is headquartered in Berlin, Germany with offices in U.K. and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. Atlas products meet the highest standards known in the industry including, ISO13485 & CE mark and US Food and Drug Administration (FDA).

The Partnership Agreement includes:

• Distribution rights by Empower for Atlas products in USA, Canada, Mexico, Central America, Australia, New Zealand
• Sales and Marketing launch of current FDA approved Atlas products in USA
• Utilization of MediSure Laboratory to seek FDA approvals for Atlas products
• Ongoing clinical study services by Empower’s MediSure Laboratory for FDA approval of Atlas products
• Support by Empower for Atlas and its partners to set up future USA manufacturing
• Potential investment by Atlas and its partners to support Empower’s growth plan

“Our partnership with Atlas will help accelerate both of our immediate growth plans in the U.S. market”, stated Steven McAuley, Chairman and CEO of Empower Clinics “Together we can generate short term revenues as a number of Atlas products are already FDA approved and only require sales and marketing support from Empower and our subsidiaries. Our longer-term collaboration can also drive further growth in the U.S. as together we secure U.S. FDA approvals for more Atlas products by leveraging our diagnostics laboratory and medical team for clinical studies.”

“We are very excited to enter the U.S. market in partnership with Empower”, said Dr. Raed Shadfan, Phd., founder of Atlas. “Atlas products and services have already seen success in Europe, Asia, and Africa. Together with Empower we look forward to growing our global presence and entering the massive U.S. market. Many of our products are already FDA approved and we were simply waiting for a partner like Empower to help us successfully expand our global reach. The combination of our global manufacturing and distribution expertise with Empower’s U.S. talent and laboratory presence is a synergy that will benefit more Americans to access affordable and convenient medical diagnostic devices.”

“Finding the right partner for the U.S. market has been a long and challenging process for our company until we met Steven McAuley”, stated Driffa Mezreg Chief of Staff

Alp Medtech AG. “Empower brings to the table the full solution we were looking for, a state-of-the-art laboratory to facilitate our regulatory needs as well as Medisure, a well-established medical device brand and distributor. We are very excited to be able to enter the U.S. market with such a strong partnership.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company with multi-disciplinary clinics, an at-home medical testing device company and state-of-the-art medical diagnostics laboratories. With a growing presence in the U.S. and Canada. Empower is a leader in integrated healthcare and diagnostics solutions and is reshaping the model for patient-first wellness.

ABOUT ATLAS MEDICAL:

Atlas Medical was established in 1996 as a manufacturer and supplier of quality Diagnostic Reagents and Kits. Our products are sold in over 80 countries worldwide. Our product range comprises a comprehensive list of quality diagnostic products in the fields of serology, hematology, microbiology, immunology, histopathology, and biochemistry. The company is located at Blankenfelde-Mahlow, Berlin, Germany .In addition to the German site, the company has offices in U.K and Turkey as well as two purpose built modern facilities in both Jordan and Malaysia. We take quality assurance very seriously and strive to produce goods to the highest standards known in the industry, including, ISO13485 & CE mark and US FDA standards. Our R&D team constantly develops and innovates novel products that significantly contribute to the advancement of the Diagnostic Industry.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:
Steven McAuley CEO
[email protected]
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
[email protected]
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the likelihood or ability for the Company to secure new testing business, that empower will granted distribution rights for US, Canada, Mexico, Central America, Australia and New Zealand, that the Empower will provide clinical study services and that such studies will result in a successful FDA approval leading to the sales and distribution of those products in the United States, that Atlas and its partners will set up USA manufacturing operations and that Empower will play a role at all, that Atlas and its partners will provide any investment support to Empower in the future. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: Empower Clinics Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company Adds New Delta-8 Tincture to Product Line

Orlando, FL , Sept. 22, 2022 (GLOBE NEWSWIRE) — Branded Legacy, Inc. (OTCQB: BLEG), a holding company focused on the commercial development of cannabinoid-infused products from CBD topicals and tinctures to edibles is pleased to announce it has partnered with Apple Rush Company, Inc., (OTC Pink: APRU), to make its Delta 8 tinctures for Spikes CBDX.

Apple Rush Company, Inc., a Texas corporation, is a company that engages in the business of developing, marketing, distributing, and selling products that promote a healthy lifestyle. Its primary focus is the food, beverage, snacks, anhydrous Hemp oil marketplace, kratom, kava, and other active ingredients. It is headquartered in Orlando, Florida.

Tony Torgerud, CEO of Apple Rush, stated “We are excited to partner with Branded Legacy on this product line. APRU has developed its own technologies in water solubility and have produced 100’s of thousand tinctures, drinks, chews, and other products.  We are excited to bring additional products to Branded Legacy and look forward to a long mutually beneficial relationship.”

Brandon Spikes, chairman of Branded Legacy, Inc., stated, “We are pleased to be working with Tony and Apple Rush Company. We had an opportunity to tour their facility in Titusville which was the deciding factor in doing business together. We look forward to building a long-lasting relationship and potentially working together on other projects as well.”

About Spikes CBDX: Spikes CBDX is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries. The Company believes that post workout recovery, with Spikes CBDX products, can lower inflammation, aid in making your body stronger, and help recover from injuries naturally. The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation. Spikes CBDX provides tinctures, lotions, moisturizer, and cryo-gel roll-ons. To view all the Spikes CBDX products please visit: spikescbdx.com.

About Elev8 Hemp: Elev8 Hemp’s mission is simple: craft the highest-quality, organic hemp products for consumers in search of a healthier, happier lifestyle. Everyone needs to get the proper amount of healthy proteins to keep them feeling better and more energetic. We source only the best organic hemp protein powders—naturally full of powerhouse amino acids and Omegas-3, 6, and 9—so we can infuse your daily coffee and tea with an abundance of minerals, vitamins, antioxidants, and fiber. www.elev8hemp.com

About Versatile Industries: Versatile Industries, LLC is an acquisition company used to incubate companies to eventually spin off into their own public vehicles. Currently owns patent for a sports training assembly called The Quickness, a solar and water treatment company Magic 1 Promotions, LLC and Astound NMN. By supplementing NMN it helps maintain NAD+ levels, ultimately slowing the effects of aging. www.astoundnmn.com

Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company’s control.

www.brandedlegacy.com
(407) 337-0642
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Deal Bolsters Curaleaf Presence and Cements Strategic Advantage in Europe’s Largest Market as Germany Readies for Adult Use

WAKEFIELD, Mass., Aug. 9, 2022 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced that Curaleaf International Holdings Limited, the company’s European holding company, has signed a definitive agreement to acquire a 55% stake in Four 20 Pharma GmbH, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis with its own product line.

The unique partnership creates a strategic pathway for Curaleaf to acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany and ensures alignment between Curaleaf and Four 20 Pharma’s current management team to rapidly build a best-in-class German business and a strong platform for Germany’s eventual adult use market. Germany currently represents the largest medical cannabis market in Europe, with a total addressable market of over €200M in 2022 and expected to grow to nearly €1bn by the end of 2024 via adult-use legalization, which is slated to begin in late 2023 or early 2024.

Four 20 Pharma is among the largest cannabis operators in Germany, with a greater than 10% market share. From its inception, Four 20 Pharma has focused on bringing top quality flower to market.

Boris Jordan, Curaleaf Executive Chairman, stated, “By partnering with Four20 Pharma, Curaleaf’s European business will immediately gain additional critical mass and be in a superior position to capitalize on the accelerating trends in the European cannabis market. The opportunity in Europe cannot be understated, and Curaleaf is uniquely differentiated from other U.S. MSOs via our already significant presence as the largest and most licensed cannabis company in Europe. With cultivation facilities in Portugal, manufacturing facilities in Spain and UK, rapidly growing patient numbers across Europe, particularly in the UK, Curaleaf serves the entire legal cannabis ecosystem and is also poised to capitalize on the adult use opportunity as regulation starts to unlock. This strategic transaction further underscores our aspiration to be the major player in the European market and the leading global cannabis company.”

Miles Worne, President of Curaleaf International, said, “Four 20 Pharma is a leading German distributor with a branded product that consumers love. They’ve captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering. As such, Four 20 Pharma is uniquely positioned to capitalize on Germany’s conversion from a medical to an adult use market and we’re thrilled to be partnering with their talented management team.”

Torsten Greif, Managing Partner of Four 20 Pharma, stated, “We have been exploring possible partners to stake our claim in the future German and European cannabis markets, and in Curaleaf we know we’ve found the undisputed leader and the best partner. From the beginning of our conversations, it was clear that they supported our strategic vision and respected our autonomy and entrepreneurial approach. Having full access to the tremendous knowledge and assets of the Curaleaf team will accelerate our future growth projects and help drive our company to the next level.”

Thomas Schatton, Managing Partner of Four 20 Pharma, added, “Curaleaf shares our values of customer dedication and commitment to product quality, and we are incredibly excited about our future together. The team at Four 20 are thrilled to be able to leverage Curaleaf’s proven R&D expertise to help us continue delivering the best quality products to our medical patients and the promising future adult use market.”

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 22 states with 136 dispensaries, 26 cultivation sites, and employs over 5,700 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

About Four20 Pharma

Four 20 Pharma is a leading, fully EU-GMP & GDP licensed European producer and distributor of medical cannabis with industry-leading product quality and best-in-class regulatory expertise. Four 20 Pharma entered the German market with the vision to guarantee continuous patient care, and since the launch in 2020 of its “420NATURAL” brand, the company has created a steady supply chain to deliver the best possible cannabis products to its patients. The company employs 41 team members and is based in Paderborn, Germany.

FORWARD-LOOKING STATEMENTS

This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the acquisition of a majority stake in Four 20 Pharma. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed March 9, 2022, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
[email protected]

MEDIA CONTACTS
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

Four20 Pharma GmbH
Christopher Thiele
[email protected]

SOURCE Curaleaf Holdings, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

No B.S. Skincare, in collaboration with Julianna Peña, Launches “Breaking stereotypes and b.s.” Campaign as Part of a Customer Acquisition Strategy

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) — Simply Better Brands Corp. (the “Company” or “Simply Better Brands”) (TSX Venture:  SBBC) (OTCQB:  PKANF) is pleased to announce a yearlong partnership with reigning UFC Bantamweight champion Julianna Peña on their No B.S. Skincare brand. The collaboration commences with the launch of their “Breaking stereotypes and b.s.” campaign focused on featuring new voices and supporting the diverse and powerful people that represent the essence of the brand.

Watch the campaign video here.

Since its beginnings in 2018, No B.S. grew a cult following by calling out the b.s. on the beauty industry and is now doing the same with some of the daily stereotypes that impact people’s relationship with self-care, while supporting the athlete’s trailblazing career in the male-dominated UFC fighting industry.

Two seemingly opposed worlds – the beauty industry and mixed martial arts (MMA) – are coming together on this campaign, building on the belief that skincare is not a gender issue, but a human issue.

“Julianna represents what No B.S. Skincare is about. She is an amazing inspiration, breaking stereotypes from all angles. Being a strong MMA fighter should not be synonymous to “manly” and taking care of your looks does not have to be synonymous to “girly”. If you want your skin to look good, it must be healthy. This is why we developed a skincare line with no toxic ingredient or B.S., and why Julianna is the perfect partner to inspire people to break stereotypes and cut out all the unnecessary, toxic B.S. they don’t need, starting with their skin care,” says Diana Briceno, CEO and founder of No B.S. Life, LLC, a subsidiary of the Company.

As the current UFC Women’s Bantamweight Champion and first woman to win The Ultimate Fighter, while taking care of herself and being a role model to her daughter, Julianna Peña’s unique life story and captivating personality stand against stereotypes around beauty, gender, strength, and athleticism.

“As a professional athlete and champion, the most important standard I set for myself is to be the best. I have no time for B.S. which is why I am so excited to be partnering with No B.S. Skincare and its products. I don’t skip steps in training, and I don’t skip steps in my skincare routine. I only use clean, effective products on my skin. And No B.S. Skincare provides exactly that—all while keeping it real. It’s an honor to be able to share my love for their products with the public so they too can benefit from these powerful formulas,” says Julianna Peña.

To demonstrate the difference that the right skin care can make on your skin, No B.S. and Julianna Peña are gifting her favorite product – the No B.S. Skincare BHA Purifying Toner with any purchase of $50 or more, using coupon code KOBS22 at livenobs.com through July 30^th, 2022.

This toner packed with tea tree oil, witch hazel and BHAs (beta hydroxy acids) is the perfect companion for athletes, fighters and people on the move to wipe away sebum, debris, and bacteria build up, keeping their skin smooth, clean and free of blemishes. The brand also ‘walks the walk’ by offering a no-questions-asked 30-day ‘Love it or Return it’ guarantee.

About No B.S. Skincare 

The No B.S. brand is committed to ousting beauty industry B.S. with clean ingredients that work smarter to give us healthy, glowing skin. They don’t promise a miracle in a bottle: they promise clean formulas, visible results, and a B.S.-free beauty culture we can all get behind. They proudly partner with organizations striving to affect real, positive change such as She Recovers, Feeding America, Project Glimmer, and Lotus House.

About Simply Better Brands Corp.

Simply Better Brands Corp. leads an international omni-channel platform with diversified assets in the emerging plant-based and holistic wellness consumer product categories. The Company’s mission is focused on leading innovation for the informed Millennial and Generation Z generations in the rapidly growing plant-based wellness, natural, and clean ingredient space. The Company continues to focus on expansion into high-growth consumer product categories including plant-based food, clean ingredient skincare and plant-based wellness.  For more information on Simply Better Brands Corp., please visit: https://www.simplybetterbrands.com/investor-relations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Simply Better Brands Corp.
Brian Meadows
Chief Financial Officer
+1 (855) 553-7441
[email protected]

Forward-Looking Information

Certain statements contained in this news release constitute “forward-looking information” ‎and “forward looking ‎statements” as such terms are used in applicable Canadian securities ‎laws. Forward-looking statements and ‎information are based on plans, expectations and ‎estimates of management at the date the information is provided ‎and are subject to certain ‎factors and assumptions, including, among others, that the Company’s financial ‎condition and ‎development plans do not change as a result of unforeseen events, the impact of the COVID-19 ‎‎pandemic, the regulatory climate in which the Company operates, the Company’s ability to ‎execute on its ‎business plans, distribution plans, reliance on a consistent supply chain, and ‎claims relating to the efficacy and results of the Company’s products. Specifically, this news ‎release contains forward-looking statements relating to, but not limited to, the Company’s partnership with Julianna Peña, product availability and gifting, product efficacy, and product guarantees. ‎

Forward-looking statements and information are subject to a variety of risks and uncertainties ‎and other factors ‎that could cause plans, estimates and actual results to vary materially from ‎those projected in such forward-‎looking statements and information. Factors that could cause ‎the forward-looking statements and information in ‎this news release to change or to be ‎inaccurate include, but are not limited to, changing consumer preferences, the ‎impacts of ‎COVID-19, that the Company’s financial condition and development plans change, ability to ‎obtain ‎necessary regulatory approvals and product viability and risk, as well as the other risks ‎and uncertainties ‎applicable to the Company and the industries in which it operates, and as set ‎forth in the Company’s filings available under the Company’s profile at ‎www.sedar.com. ‎

There is no representation by the Company that actual results achieved will be the same in ‎whole or in part as ‎those referenced in the forward-looking statements and the Company does ‎not undertake any obligation to update ‎publicly or to revise any of the included forward-‎looking statements, whether as a result of new information, ‎future events or otherwise, except ‎as may be required by applicable securities law.‎

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Kiva Sales and Service Will Assist Jones Soda Co. In Launching Their First-Ever Cannabis-Infused Beverage, Mary Jones, Into The California Market

OAKLAND, Calif., June 22, 2022 /PRNewswire/ — Jones Soda Co. (OTCQB: JSDA) (CSE: JSDA), the original craft soda known for its unconventional flavors and user photo-submitted labels, today announced an exclusive partnership with Kiva Sales and Service (KSS), the industry-leading sales and distribution platform offering dispensaries a complete suite of curated, best-in-class brands, to launch its new line of cannabis-infused beverages, Mary Jones, into the California market.

“We couldn’t be more excited to share Mary Jones with our fans, budtenders, and retailers throughout California,” stated Bohb Blair, CMO, Jones Soda. “Partnering with KSS has allowed us to hit the ground running and ensure timely distribution and service to the top dispensary locations throughout the state.”

Mary Jones is the first cannabis product portfolio to leverage 25 years of a mass market-established equity across brand, beverage, flavors, and fans. The portfolio uniquely fills a gap that exists in the market between micro-dosed, health claim-driven brands and high-potency terpene flavor profile brands by offering both new and experienced users a welcome alternative for cannabis moments and social occasions.

“We are humbled to welcome Mary Jones and the Jones Soda family to the Kiva Sales and Service portfolio. Mary Jones is a truly unique offering in the California cannabis space and brings what I believe to be the new leader in infused soda pop,” commented KSS President Brooks Jorgensen. “We could not be more excited about the future of this brand.”

At launch, Mary Jones will feature a line of 10mg THC cannabis-infused sodas sold in single dose, 12-oz bottles, with a four-pack carrier ideal for social occasions and sharing. All products are available in Jones’ fan-favorite Root Beer, Berry Lemonade, Green Apple, and Orange & Cream flavors, with a rotating selection of seasonal and limited-edition flavors planned for future release. The Jones flavor science team designed each of these products to perfectly recreate Jones’ popular mainline soda flavors, delivering crave-worthy beverages.

Kiva Sales and Service has extensive experience in elevating groundbreaking products, while offering a visionary approach to connect with new, untapped cannabis consumers. This new partnership will accelerate expansion of Mary Jones’ products throughout California via strategic deployment of distribution resources, and an integrated sales approach between Mary Jones and KSS sales teams.

For more information on Mary Jones’ product offerings and retailers, visit https://www.jonessoda.com/ and follow the brand on Instagram at @jonessodaco.

About Jones Soda Co.

Jones Soda Co.® (CSE: JSDA, OTCQB: JSDA) is a leading craft soda manufacturer with a subsidiary dedicated to cannabis products. The company markets and distributes premium craft sodas under the Jones® Soda and Lemoncocco® brands, and a variety of cannabis products under the Mary Jones brand. Jones’ mainstream soda line is sold across North America in glass bottles, cans and on fountain through traditional beverage outlets, restaurants and alternative accounts. The company is headquartered in Seattle, Washington. For more information, visit www.jonessoda.com, www.myjones.com, or www.drinklemoncocco.com.

About Kiva Sales & Service

In 2010, we at Kiva made a commitment to never release a product to our customer until it was perfect. We used that same philosophy as our driving mission at Kiva Sales & Service to make sure we provide the best customer service of any distributor in the market. Our goal is to build the leading distributor for premium California cannabis brands with a strong focus on service, brand building, and relationships that will accelerate growth for all our partners executed by a single distributor for all of their California strategy. With our commitment to dispensary service and a curated portfolio of industry-leading cannabis brands, we can be stronger together

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, Ontario–(Newsfile Corp. – May 31, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to acquire 100% of Dyscovry Science Ltd., a Toronto-based biotechnology company. Dyscovry focuses on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome. With Dyscovry’s research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives.

“We have been working with Brad Dottin and his team at Dyscovry for almost a year now planning this transaction,” commented Mike Arnold, Silo Wellness’s president and founder. “We have watched the psychedelic market get pummeled as many have been chasing the ‘me too’ pharma deals, while we stayed focused on preparing for Oregon adult use with a successful Jamaican retreat model while, in the background, working on this unique opportunity. For the first time under one roof, a publicly traded company will provide psychedelic healing right now through Jamaican psychedelic wellness retreats while at the same time innovating the ‘what’s next’ for psychedelic pharmaceutical healing. As an Oregon attorney who founded Silo Wellness in 2018 with the goal of preparing for psilocybin legalization in Oregon, I wanted to ensure that natural psychedelics were never locked up solely behind a pharmacy window controlled by corporations. Our planned acquisition of Dyscovry shows that traditional medicines can coexist alongside modern scientific innovation.”

“The Dyscovry team has spent the last two years looking at the emerging psychedelic pharmaceutical startups and then seeing them tested against the market,” stated Brad Dottin, founder and president of Dyscovry. “What can they produce by way of value and what models work? What pharma deals have been successful in the natural plant molecule space? We saw that most have lost considerable value along with the rest of the sector after initial marketing pushes exited many of the original shareholders.”

“We wanted to develop something unique with our public and private research collaborations,” Mr. Dottin continued. “Our Chief Science Officer Dr. Ronald Stead and his team at Holburn Biomedical are leading the studies of the anti-inflammatory effects of psilocybin as related to gut health with intended clinical trials. With access to Canadian federal government research laboratories for developing biosynthetic manufacturing processes, a university laboratory for animal studies, and a DEL facility for pre-clinical research, human capital is the priority over potentially wasteful capital expenditures.”

“We have intended to differentiate Dyscovry,” stated Gerard Lee, Chief Executive Officer of Dyscovry, “and de-risk our psychedelic pharmaceutical opportunity by assembling the key components to create a comprehensive pharmaceutical corporation with psilocybin and its derivatives targeting a physiological condition, IBS. Dyscovry has the facilities, IP, clinical research, and the public and private collaborations required to begin to advance this initiative. By Dyscovry’s research team focusing on investigating a quantifiable anti-inflammatory effect of psychedelics, Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psilocybin, as an alternative therapeutic option to both naturally-occurring and chemically-synthesized psilocybin. The downstream goal is to bring regenerative medicine approaches to the treatment of IBS.”

Dyscovry’s vision is to create a pharmaceutical platform and exit strategy similar to what GW Pharma did with their cannabinoid manufacturing and clinical product. Furthermore, Dyscovry intends to not only use any resulting APIs to supply its own clinical research but to compete with synthetic psilocybin for research purposes to generate revenue in the nearer term. Silo Wellness hopes to ultimately create a combined entity focused on pharmaceutical API revenue along with revenue from the CPG market via Marley One and through “psychedelic healing now” via the psychedelic retreat model.

“Our vision for Silo Wellness is a de-risking platform for psychedelic investors,” Arnold explained. “We believe we will be the only company with deep roots in Oregon that is actively providing psilocybin to paying guests in the western hemisphere (Jamaica) while at the same time working a pharmaceutical opportunity (Dyscovry). In other words, if the future of psychedelic medicine is a state-by-state legalization akin to cannabis, we intend to have you covered. If the future is pharma, we have an asset for you as well. If these parallel avenues go forward simultaneously with a thriving adult use market in addition to pharma, then freedom wins, and the world is better for it. We intend to be a leader in the space and hope to bring inexpensive psychedelic healing to as many people in need as possible.”

Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates the Company acquiring 100% of Dyscovry’s shares in exchange for 49% of the issued outstanding securities of the Company. Further details will be announced once made available.

ABOUT DYSCOVRY

DYSCOVRY SCIENCE LTD is an innovative Toronto-based biotechnology company conducting research to establish a world-leading position in the development of fungal- and plant-derived therapeutics through its proven drug discovery and development processes, its growing intellectual property portfolio, and regulatory and manufacturing expertise.

Dyscovry is led by an experienced team with government, university and private collaborations focusing on biosynthesis of psilocybin and investigating a quantifiable anti-inflammatory effect of psychedelics – believed to be mediated through 5-HT2A activation – and how this relationship pertains to disorders that affect the large intestine. Dyscovry is focused on indications such as Irritable Bowel Syndrome (IBS) that inflict suffering on a double digit percentage of the entire human global population. This suffering includes the physiological symptoms but also the secondary psychological symptoms from living with this disease.

www.Dyscovry.com

ABOUT SILO WELLNESS

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has a presence in both Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: 3K70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

For more information about Silo Wellness, please visit www.silowellness.com.

Silo Wellness Company Contact:
Mike Arnold, President
541-900-5871
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking information may relate to anticipated events or results including, but not limited to the closing of the acquisition with Dyscovry Science Ltd., and the Company’s future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness’s continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.